Masatoshi Kudo

Sapporo Medical University — Japan

Medicine · Health Sciences

142h-index124.1kcitations2.8kworks11.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(1145), Liver Disease Diagnosis and Treatment(534), Pancreatic and Hepatic Oncology Research(298), Cancer Immunotherapy and Biomarkers(191), Colorectal Cancer Treatments and Studies(189)

Publications2.4k total

Utility of Biomarker Panels in the Surveillance and Monitoring of Hepatocellular Carcinoma: Consensus Statements from an International Delphi Panel
Liver Cancer·2025Open Access
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis
Liver Cancer·2025Open Access
Cytomegalovirus-induced intrahepatic cholestasis complicated by hemophagocytic syndrome in an immunocompetent adult
Clinical Journal of Gastroenterology·2025Open Access
Response to the letter to the editor regarding “Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients”
Pancreatology·2025
Data from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma
2025Open Access
275MO Overall efficacy outcomes of nivolumab plus ipilimumab by occurrence of immune-mediated adverse events (IMAEs) and additional safety from Asian patients in CheckMate 9DW
Annals of Oncology·2025
Supplementary Data 1 from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma
2025Open Access
No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study
Cancers·2025Open Access
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study
Hepatology Research·2025· 1 cited
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
JHEP Reports·2025Open Access
Possible Involvement of the Mucosal Claudin Expression in the Healing of a Refractory Ileocecal Ulcer in a Patient with Crohn's Disease Successfully Treated with Infliximab
Internal Medicine·2025· 1 citedOpen Access
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
Hepatology Research·2025Open Access
Caloric Restriction is Associated With Enhanced Clinical Outcomes in Hospitalized Patients With Ulcerative Colitis
Gastro Hep Advances·2025· 1 citedOpen Access
Lancet Commission 2025 Calls for Urgent Global Action: 60% of Liver Cancers Are Preventable
Liver Cancer·2025Open Access
Atezolizumab Plus Bevacizumab for <scp>TACE</scp> ‐Unsuitable Intermediate‐Stage <scp>HCC</scp> Beyond Up‐To‐7 Criteria: Final Analysis of <scp>REPLACEMENT</scp>
Liver International·2025· 2 citedOpen Access
206P Development of a machine-learning model on pre-treatment characteristics to predict long-term survivorship to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
ESMO Real World Data and Digital Oncology·2025Open Access
Multimodal tilmanocept for preoperative imaging and fluorescence-guided surgery of porcine lateral pelvic sentinel lymph nodes
Scientific Reports·2025· 1 citedOpen Access
Roles of Deubiquitinases OTUD3 and OTUD5 in Inflammatory Bowel Diseases
International Journal of Molecular Sciences·2025· 1 citedOpen Access
Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial
Signal Transduction and Targeted Therapy·2025· 4 citedOpen Access
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
JHEP Reports·2025· 3 citedOpen Access
page 1 of 121Next →

Frequent Co-authors

Ann‐Lii Cheng(15), Shukui Qin(12), Richard S. Finn(10), Yoon‐Koo Kang(10), Andrew X. Zhu(9), Byung Ihn Choi(8), Masafumi Ikeda(7), Norihiro Kokudo(7), Takuji Okusaka(7), Christoph F. Dietrich(7), R. Graham Barr(7), Namiki Izumi(7), В. В. Бредер(6), Philippe Merle(6), Ho Yeong Lim(6), Kwang‐Hyub Han(6), Joong‐Won Park(6), Bruno Sangro(6), Thomas Yau(6), Josep M. Llovet(6)